BioNTech SE (BNTX) Long-Term Debt Repayments (2019 - 2025)
BioNTech SE (BNTX) posted Long-Term Debt Repayments of -$10.0 million for Q4 2025, down 613.59% sequentially from -$1.4 million in Q3 2025.
BioNTech SE (BNTX) Long-Term Debt Repayments (2019 - 2025) Analysis & Trends
BioNTech SE has reported Long-Term Debt Repayments for 7 years, with the latest figure at -$10.0 million in Q4 2025.
- Quarterly Long-Term Debt Repayments changed N/A year-over-year to -$10.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$20.3 million (up 99.29% YoY) and the FY2025 annual result came in at -$20.3 million, down 727.44% from the prior year.
- Long-Term Debt Repayments declined to -$10.0 million in Q4 2025 per BNTX's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Long-Term Debt Repayments peaked at $1.8 billion in Q4 2023 and troughed at -$2.9 billion in Q1 2024.
- A 5-year average of -$194.5 million and a median of -$2.5 million in 2024 frame the typical range for Long-Term Debt Repayments.
- The sharpest annual moves came in 2022 and 2025: Long-Term Debt Repayments sank 2498912357.2% in 2022, then surged 99.83% in 2025.
- Over 5 years, Long-Term Debt Repayments stood at -$58.0 in 2021, then plunged by 32682274.62% to -$19.0 million in 2022, then jumped by 9772.67% to $1.8 billion in 2023, then slumped by 100.14% to -$2.5 million in 2024, then slumped by 304.18% to -$10.0 million in 2025.
- According to Business Quant data, Long-Term Debt Repayments over the past three periods registered -$10.0 million, -$1.4 million, and -$4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 17.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -10.01 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.01 Mn |
| Dec 31, 2025 | -10.01 Mn |
| Sep 30, 2025 | -1.40 Mn |
| Sep 30, 2025 | -1.40 Mn |
| Jun 30, 2025 | -4.19 Mn |
| Jun 30, 2025 | -4.19 Mn |
| Mar 31, 2025 | -4.73 Mn |
| Mar 31, 2025 | -4.73 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Mar 31, 2024 | -2.86 Bn |
| Mar 31, 2024 | -2.86 Bn |
| Dec 31, 2023 | 1.83 Bn |
| Dec 31, 2023 | 1.83 Bn |
| Sep 30, 2023 | -108,859.05 |
| Sep 30, 2023 | -108,859.05 |
| Mar 31, 2023 | -1.83 Bn |
| Mar 31, 2023 | -1.83 Bn |
| Sep 30, 2022 | -18.96 Mn |
| Sep 30, 2022 | -18.96 Mn |